MedInCell Shares Drop 3% in Session but Still Up +59% Year-Over-Year
Shares of the biotech company based in Montpellier dropped nearly 3% this Thursday, in a Paris market weighed down by a tense geopolitical context. Despite this decline, the stock maintains a nearly 59% annual increase, demonstrating a strong long-term stock market performance.
In today's trading session on April 2, MedInCell fell by 2.84% to 22.60 euros, down from yesterday's close of 23.26 euros. This decline is part of a challenging session for the Parisian market: the CAC 40 is down 1.25% and the SBF 120 has retreated by 1.26%. The healthcare sector is not immune to the downturn, as evidenced by the declines in Sanofi (-0.74%) and UCB (-3.14%). Technically, the stock is trading below its 50-day moving average (23.31 euros) and its 200-day moving average (23.49 euros), indicating selling pressure in the short and medium term. The RSI, at 55, remains in the neutral zone, suggesting that the stock is neither overbought nor oversold. The nearest support lies at 20.24 euros, about 10% below the current price, which could act as a floor if the decline continues. However, the performance over the past week remains positive (+3.58%), which puts the day's movement into perspective. Over three months, the performance is negative, with a 10.32% decline, reflecting a consolidation phase that began earlier in the year.
Key Upcoming Events for Investors
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Investors in the biotech company, which specializes in prolonged-action drug delivery technologies, have several important dates to mark on their calendars. The annual results for the fiscal year 2025-2026 are expected on June 16, an event that could shed new light on the company's financial trajectory. The general assembly is scheduled for September 10, followed by the results of the first half of 2026-2027 on December 8. The stock's beta, close to zero (0.01), indicates that it largely moves independently of major indices. This characteristic, common to many biotech stocks, means that price movements are more dependent on specific catalysts — such as clinical advancements, partnerships, or financial publications — than general market fluctuations. The monthly volatility of 14.56% remains moderate for a company of this profile, suggesting a relatively stable stock within its segment. With an annual performance of nearly 59%, the stock has significantly outperformed the CAC 40 over the past year. The upcoming results publication in June will be a crucial test to determine if this trajectory is based on solid fundamentals.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Context
Period
Period: 9M 2025
Guidance from the release
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
